Synteract Strengthens Biostats Team with Oncology Expert Eric Bissonette
RESEARCH TRIANGLE PARK, NC – Sep. 24, 2018 – Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has added Eric Bissonette, MS, a seasoned multidisciplinary clinical trial expert, as biostatistics director. His role supports Synteract’s mandate to add clinical strategists with cross-functional expertise in developing and operationalizing global strategies.
Bissonette has more than 22 years of biostatistics experience, specializing in oncology, hematology, and immunotherapy and broad experience in a variety of other therapeutic areas. He served as the lead for biometrics functions on numerous studies and programs in clinical oncology and oncology supportive care. Aside from traditional CRO experience, Bissonette has worked in an NCI-designated Cancer Center, leading to deep understanding of the interplay between biostatistics, clinical operations, and the ultimate success of a trial. Additionally, he is a skilled programmer and lead biostatistician for Phase I-IV and non-interventional trials.
In his role, Bissonette provides leadership in complex studies, with a focus on oncology trials, especially programs with statistical methodology and challenging output quality needs. He develops or reviews relevant sections of clinical protocols, provides input on study design, defines relevant statistical endpoints and tests, as well as reviews randomization methods and estimation of sample size.
“Eric’s biostatistics background, with a particular focus in oncology, further enables our team to provide clients with multidisciplinary experience to deliver high quality, innovative, and efficient studies expediting the journey of bringing new medicines to market” said Senior Vice President of Biometrics at Synteract Mary Mattes. “His scientific acumen and therapeutic expertise elevates our biostatistics offering.”
Synteract offers a comprehensive suite of biostatistical services: as an integrated part of a full-service offering supporting studies, programs, and submissions; as a consulting service to deliver strategic input and insights at all phases of clinical development; and as a standalone service to augment clients in-house capabilities.
